SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta is gaining traction due to its high throughput, processing millions of transactions per second, and its potential to become a compliant infrastructure solution for traditional finance. The project's interoperability with other chains and integration with a Stripe company, Bridge, are also key talking points. Community discussions revolve around Keeta's infrastructure edge and possible undervaluation compared to competitors.

Yee is a community based memecoin with one mission: to fight Pepe again. Made to honor the iconic meme rivalry we all know and love.  The Yee Legend  [Filed by: Yee’s Archivist & Legal Representative]  There’s something the meme world refuses to talk about: Pepe the Frog stole Yee the Dino’s entire launch plan.  Yee had been preparing for his comeback for months, but Pepe launched two weeks earlier, hijacking Yee’s concept and selling it as his own.  The charges? Meme theft, intellectual forgery, and historical erasure.  Yee’s official contract was filed in April 2023, right after Pepe’s surprise drop. This wasn’t timing—it was theft. The archives are about to open, and history is about to be corrected

Yee Token

$YEE is trending as community members rally around its potential within the Ethereum ecosystem, citing a unique narrative and strong community-driven momentum. Many believe $YEE is poised for a significant breakout, drawing comparisons to past meme coin successes and highlighting its potential for substantial growth. Enthusiasts are actively encouraging others to 'study' $YEE and join the movement, emphasizing its connection to the resurgence of ETH.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs ($PL) is trending as investors digest the potential impact of its partnership with Google to build AI data centers in space, dubbed "Project Suncatcher". The community views this as a game-changer that could transform Planet Labs into a space infrastructure company, driving long-term revenue growth beyond satellite imagery. Bullish sentiment is high, with some speculating about a possible acquisition by Google and significant price appreciation.

The Coca-Cola Co. engages in the manufacturing and marketing of non-alcoholic beverages. It operates through the following segments: Europe, Middle East and Africa, Latin America, North America, Asia Pacific, Global Ventures, and Bottling Investments. The company was founded by Asa Griggs Candler on May 8, 1886 and is headquartered in Atlanta, GA.

Coca-Cola Co

Coca-Cola (KO) is trending as investors discuss a leadership transition with Henrique Braun named as the next CEO in 2026. While some view the change as unlikely to cause volatility, others are analyzing the stock's technicals, with community chatter focused on potential shakeouts and key support levels. Some traders are eyeing potential bullish reversals given oversold conditions, while others express frustration with the stock's price action and debate its premium valuation.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CRWV is trending due to a convertible note offering, sparking community debate about the company's debt and future prospects. While some investors express concern over potential dilution and financial health, others view the offering as a strategic move for long-term growth in the AI cloud sector. Discussions also revolve around CRWV's competitive positioning and potential impact from broader industry news, like Oracle's earnings.

Polestar Automotive Holding UK Plc is the Swedish electric performance car brand that engages in the research, development, marketing, commercialization, and sales of battery electric vehicles and related technology solutions. It offers Polestar 2 (PS2), a premium fast-back sedan, the Polestar 3 (PS3), a luxury aero sport-utility vehicle, the Polestar 4 (PS4), a premium sport utility vehicle, the Polestar 5 (PS5), a luxury sport grand-touring sedan, and the Polestar 6 (PS6), a luxury roadster. The company was founded on September 15, 2021 and is headquartered in Gothenburg, Sweden.

Polestar Automotive Holding UK PLC - ADR Class A

Polestar ($PSNY) is trending amid discussions of a potential reverse stock split and overall financial health, with some traders pointing out a possible short squeeze due to limited share availability and upcoming reporting this week. Despite some positive sentiment around sales numbers, the community is also discussing potential red flags on the balance sheet, high cash burn, and concerns about the stock's long-term viability within the competitive EV sector.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors anticipate earnings and potential updates on QNX technology, with the community showing increasing optimism for QNX's long-term potential in the automotive and IoT sectors. Bullish sentiment is further fueled by technical signals like golden crosses and wedge formations. Community members express growing confidence in the company's future revenue and profitability.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

MSOS is trending as investors speculate about potential rescheduling catalysts, including a possible Supreme Court decision and the potential for executive action. Community members are weighing the implications of rescheduling for US cannabis companies versus Canadian LPs, and anticipating significant gains if these catalysts materialize. Many are expressing frustration and caution due to previous false starts and disappointments in the sector.

ONDO is a DeFi primitive that enables users to originate risk-isolated, fixed yield loans backed by yield-generating crypto-assets. It's unique because it's a permissionless protocol that allows users to interact on a peer-to-pool basis with no intermediaries.

Ondo

ONDO is trending as the community discusses its potential in the tokenized real-world asset (RWA) space and upcoming catalysts. Speculation surrounds possible integrations with traditional finance, including potential partnerships with BlackRock and the launch of tokenized stocks. Some traders are closely watching a large token unlock event in January 2026.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending amid analyst downgrades and discussions around management's communication strategy following recent comments about branded checkout growth; however, some investors believe the negative sentiment is overblown and the stock is undervalued, highlighting buyback programs and potential partnerships as positives, while the community debates whether a bottom has been reached.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>CEO John C. Jacobs noted that over the past eight quarters, the company has achieved approximately $1.1 billion in non-dilutive cash flow, including $800 million from its partnerships.</li><li>For the third quarter, the company reported total revenue of $70 million, including $48 million from Sanofi, $6 million from Takeda, and $2 million from other partners.</li><li>Novavax now expects full-year adjusted revenue in the $1.04 billion to $1.06 billion range. &nbsp;</li></ul>Novavax (NVAX) CEO John C. Jacobs on Thursday detailed the company’s efforts beyond its COVID-19 vaccine, including expanding partnerships with Sanofi and Takeda.“Our new strategy is centered on amplifying the impact of our technology platform through collaborations with other biopharmaceutical companies and a new diversified pipeline, and this represents a strategic and thoughtful departure away from a single focus on the resource-intense commercialization of one product, our COVID-19 vaccine,” the CEO said.Jacobs noted that over the past eight quarters, the company has achieved approximately $1.1 billion in non-dilutive cash flow, including $800 million from its partnerships in the form of upfront payments and milestones earned to date.The company recently expanded on its Sanofi partnership to include its Matrix-M adjuvant in Sanofi’s pandemic influenza vaccine candidate program. It also renegotiated its deal with Takeda in a bid to grow revenues from the latter's activities involving Nuvaxovid vaccine in Japan.<h2 class="st-heading-2">Q3 Numbers</h2>For the third quarter, the company <a href="https://stocktwits.com/symbol/NVAX">reported</a> total revenue of $70 million, including $48 million from Sanofi, $6 million from Takeda, and $2 million from other partners. This marks a dip from the $80 million reported in the corresponding quarter of 2024, but above an analyst estimate of $44.87 million.The company now expects full-year adjusted revenue in the $1.04 billion to $1.06 billion range, up from its previous guidance of $1 billion to $1.05 billion. This is primarily owing to better than previously expected licensing, royalty, and other revenue.The company’s loss per share came in at $1.25 in the third quarter, above an expected loss of $1.13.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVAX">NVAX stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:623/57;" src="data:image/png;base64,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" width="623" height="57" alt="NVAX's Sentiment Meter and Message Volume as of 1:12 p.m. ET on Nov. 6, 2025 | Source: Stocktwits"><figcaption>NVAX's Sentiment Meter and Message Volume as of 1:12 p.m. ET on Nov. 6, 2025 | Source: Stocktwits</figcaption></figure>NVAX stock is down by about 4% this year and by about 14% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-reportedly-refrains-from-backing-down-in-metsera-acquisition-battle-sweetens-bid-further/cL2twEeRER8">Novo Nordisk Reportedly Refrains From Backing Down In Metsera Acquisition Battle, Sweetens Bid Further</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, a medical syringe is displayed on a screen, and the logo of Novavax in the background. (Photo Illustration by Nikos Pekiaridis/SOPA Images/LightRocket via Getty Images)

Novavax Sees Higher Revenue From Partners For Full-Year, Raises Revenue Guidance

The company recently expanded on its Sanofi partnership to include its Matrix-M adjuvant in Sanofi’s pandemic influenza vaccine candidate program.

Equity

The company recently expanded on its Sanofi partnership to include its Matrix-M adjuvant in Sanofi’s pandemic influenza vaccine candidate program and renegotiated its deal with Takeda in a bid to grow revenues from the latter's activities involving Nuvaxovid vaccine in Japan. 

<ul class="summary-bullets"><li>In Q3, Ibsrela saw highest demand since launch and recorded revenue of $78.2 million, marking a growth of 92%.</li><li>Ardelyx’s net loss in the quarter, however, was $1 million, compared to net loss of $0.8 million reported in the corresponding quarter of 2024.</li><li>The company is now looking forward to filing an investigational new drug submission to the FDA for its early-stage candidate RDX10531 in 2026.&nbsp; &nbsp;</li></ul>Ardelyx shares soared 22% in Friday’s premarket session after the company raised guidance for its irritable bowel syndrome drug Ibsrela, which saw the highest demand in the third quarter (Q3).“IBSRELA continues to outperform and is the foundation of our portfolio and the main engine for Ardelyx's future growth,” CEO Mike Raab said on the company’s earnings call on Thursday.“Demand growth is broad-based and demonstrates how vital this therapy is for patients. We expect this momentum to continue through Q4 and beyond, and as a result, we are raising our guidance,” he added.<h2 class="st-heading-2">Revised Guidance, Q3 Fineprint</h2>The company now <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.ardelyx.com/news-releases/news-release-details/ardelyx-reports-third-quarter-2025-financial-results-and">expects </a>revenue to be between $270 million and $ 275 million from Ibsrela for the full year. In the third quarter, the drug generated revenue of $78.2 million, marking a growth of 92%, and accounting for 74% of the company’s total product revenue for the period.U.S. revenue for Xphozah, used to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis, was $27.4 million in Q3 despite dynamic market situations, the company said. Ardelyx now expects continued growth in the fourth quarter for the drug.Total revenue in the quarter, including product and licensing revenue, came in at $110.3 million, above an analyst estimate of $100.54 million. Net loss in the quarter was $1 million, slightly wider than the $0.8 million net loss reported in the corresponding quarter of 2024.<h2 class="st-heading-2">Future Pipeline</h2>In the third quarter, Ardelyx began developing RDX10531, an early-stage drug candidate. The company is now looking forward to filing an Investigational New Drug submission with the U.S. Food and Drug Administration for the candidate in 2026, to initiate trials in humans.“We are committed to building a broad, sustainable pipeline, capitalizing first on an internal asset while, in parallel, we explore external opportunities,” Raab said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ARDX">ARDX stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:623/57;" src="data:image/png;base64,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" width="623" height="57" alt="ARDX's Sentiment Meter and Message Volume as of 8:50 a.m. ET on Oct. 31, 2025 | Source: Stocktwits"><figcaption>ARDX's Sentiment Meter and Message Volume as of 8:50 a.m. ET on Oct. 31, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user sees the stock hitting a per-share price of $7 today.<stembedurl>https://stocktwits.com/badgermobile/message/634454149</stembedurl>Another expressed optimism about the CEO saying on the earnings call that it is open to external business opportunities.<stembedurl>https://stocktwits.com/Dragan7/message/634447443</stembedurl>ARDX stock is down 1% year-to-date and by approximately 15% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-shareholder-gavin-baker-supports-elon-musk-1-trillion-pay-plan/cLGqGXNR3Ul">Atreides’ Gavin Baker Backs Elon Musk’s $1T Tesla Pay Deal Despite Broad Opposition</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Ardelyx logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Ardelyx Shares Soar Premarket As CEO Sees Continued Demand For Blockbuster Drug Ibsrela

The company now expects revenue from Ibsrela to be between $270 million and $275 million for the full year.

<ul class="summary-bullets"><li>ADX-629 was administered orally for one month in four patients with mild to moderate alcohol-associated hepatitis in the study.</li><li>Statistically significant improvement relative to baseline was observed in clinically relevant objective markers of hepatic function and inflammation, the company said.&nbsp;</li><li>The company has, however, &nbsp;now discontinued clinical development of ADX-629 pending further investigator-sponsored clinical testing in Sjögren-Larsson Syndrome.&nbsp; &nbsp;</li></ul>Aldeyra Therapeutics, Inc. (ALDX) on Tuesday announced that its experimental drug candidate ADX-629 demonstrated statistically significant improvement in liver function in patients with alcohol-associated hepatitis in a mid-stage trial.ADX-629 was administered orally for one month in four patients with mild to moderate alcohol-associated hepatitis in the study. Statistically significant improvement relative to baseline was observed in clinically relevant objective markers of hepatic function and inflammation, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-announces-positive-results-phase-2-clinical">said.</a>No serious adverse events were reported in the trial, the company noted. Furthermore, no adverse events were deemed related to its experimental drug, it added.<h2 class="st-heading-2">Plans Ahead</h2>The company has, however, &nbsp;now discontinued clinical development of ADX-629 pending further investigator-sponsored clinical testing in Sjögren-Larsson Syndrome, a rare genetic disorder.CEO Todd C. Brady said that the company will share details of the recent trial in the future and will now focus its pipeline on ADX-248 and ADX-246 for the treatment of immune-mediated diseases.While ADX-248 is being studied in the treatment of metabolic inflammation, including obesity and hypertriglyceridemia, ADX-246 is being studied for the treatment of dry form of age-related macular degeneration.Aldeyra is committed to developing a robust pipeline of novel therapeutics in a fiscally prudent manner to maintain growth, the CEO noted.The company now expects cash, cash equivalents, and marketable securities to provide operational runway into the second half of 2027.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ALDX">ALDX stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.ALDX stock is down by 0.5% this year and by about 12% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-registrations-slumped-nearly-19-percent-in-eu-in-september-despite-rising-ev-demand/cLGjW7LR3HL">Tesla Registrations Slumped Nearly 19% In EU In September Despite Rising EV Demand</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Aldeyra Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Aldeyra Reports Positive Mid-Stage Data For Liver Drug, Discontinues Further Development

Statistically significant improvement relative to baseline was observed in clinically relevant objective markers of hepatic function and inflammation in the study, the company said. 

<ul class="summary-bullets"><li>Inhibrx Biosciences announced that its drug Ozekibart yielded positive results in a registrational trial for a rare type of bone cancer.</li><li>In the study, Ozekibart achieved a 52% reduction in the risk of disease progression or death compared to placebo, more than doubling median progression-free survival to 5.52 months.</li><li>According to Inhibrx, Ozekibart is the first investigational therapy to demonstrate a significant PFS benefit in a randomized trial for chondrosarcoma. &nbsp;</li></ul>Shares of Inhibrx Biosciences (INBX) jumped over 62% in the pre-market session on Friday after the company announced that its drug Ozekibart yielded positive results in a registrational trial for a rare type of bone cancer.The company investigated Ozekibart as a single agent versus placebo in patients with advanced or metastatic, unresectable chondrosarcoma, a rare type of bone cancer that develops in the cartilage cells, most often affecting the pelvis, thigh, or upper arm.<h2 class="st-heading-2">What Was Observed In The Study?</h2>In the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://inhibrxbiosciences.investorroom.com/2025-10-23-Inhibrx-Biosciences-Reports-Positive-Topline-Results-from-its-Registrational-Trial-of-Ozekibart-INBRX-109-in-Chondrosarcoma-and-Provides-Updates-on-Colorectal-Cancer-and-Ewing-Sarcoma-Expansion-Cohorts">study</a>, Ozekibart achieved a 52% reduction in the risk of disease progression or death compared with placebo, more than doubling median progression-free survival to 5.52 months versus 2.66 months with placebo. Progression-free survival (PFS) is the time a patient lives with a disease without worsening, from the start of treatment until disease progression or death.According to Inhibrx, Ozekibart is the first investigational therapy to demonstrate a significant PFS benefit in a randomized trial for chondrosarcoma.<h2 class="st-heading-2">Safety Concerns</h2>Ozekibart was generally well tolerated, with a manageable safety profile, the company said. However, one liver damage-related fatal event occurred early in the study, it noted. The company mitigated the risk during the course of the trial by excluding patients with severe liver impairment and by implementing close monitoring during early treatment cycles, thereby reducing the overall incidence of liver-related treatment-related adverse events, it added.Inhibrx is also studying the drug in colorectal cancer and ewing sarcoma in combination with other drugs. While colorectal cancer is a cancer that forms in the colon or rectum, ewing sarcoma is a type of cancer that forms in the bone or soft tissue.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around<a href="https://stocktwits.com/symbol/INBX"> INBX stock </a>jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels. Retail chatter around the stock jumped about 985% over the past 24 hours, according to Stocktwits data.<figure class="image"><img style="aspect-ratio:584/62;" src="data:image/png;base64,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" width="584" height="62" alt="INBX's Sentiment Meter and Message Volume as of 7:00 a.m. ET on Oct. 24, 2025 | Source: Stocktwits"><figcaption>INBX's Sentiment Meter and Message Volume as of 7:00 a.m. ET on Oct. 24, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects the stock to rally as high as over $70, citing the company’s first-mover advantage in developing drugs for chondrosarcoma.<stembedurl>https://stocktwits.com/spaumaki/message/633545900</stembedurl>INBX stock is up 84% this year.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/reliance-increases-crude-imports-from-middle-east-u-s-amid-russian-crude-sanctions-report/cLGJZgVR3so">Reliance Increases Crude Imports From Middle East, U.S. Amid Russian Crude Sanctions: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Is INBX Stock Rising Today?

Inhibrx Biosciences announced that its drug Ozekibart yielded positive results in a registrational trial for a rare type of bone cancer.

EMJ Capital President Eric Jackson on Wednesday expressed optimism about Sana Biotechnology (SANA) stock, saying it could become “the next 100-bagger platform.”SANA shares traded 35% higher at the time of writing.Jackson <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/ericjackson/status/1978460243001782649">took</a> to the social media platform X, opining that <a href="https://stocktwits.com/symbol/SANA">SANA stock</a> would eventually explode, and highlighted the company’s various achievements, including its work in type 1 diabetes treatment. In January, Sana said that following a transplant of an allogeneic primary islet cell therapy into a patient with type 1 diabetes, they started producing insulin. The therapy was engineered with Sana’s hypoimmune (HIP) technology, enabling the transplantation without the need for immunosuppression.<figure class="image"><img style="aspect-ratio:592/407;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_15_at_11_35_05_AM_png_c72bd5dfe0.webp" alt="Screenshot 2025-10-15 at 11.35.05 AM.png" width="592" height="407"><figcaption>Screenshot of Jackson's X Post</figcaption></figure>Transplants generally require lifelong immunosuppression, but Sana’s technology removes the need for them, Jackson noted. ‘That’s not hype — it’s human proof that Sana’s “hypoimmune” cells can hide from the immune system and work normally. If it works in diabetes, it could work for liver, heart, muscle, or brain cells next,’ he wrote, expressing hopes for the technology powering future therapies for autoimmune diseases, cancer, and even organ regeneration.Jackson further highlighted that the biotech company’s balance sheet is solid and added that he was long on SANA stock. He also highlighted several upsides, including 9 million people with diabetes worldwide who might benefit from the treatment.“If Sana’s therapy costs $100K per patient (typical for cell therapy) and reaches only 10% of them, that’s $90B in revenue potential over time,” Jackson said.On Stocktwits, retail sentiment around SANA jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume jumped from ‘high’ to ‘extremely high’ levels.SANA stock has more than tripled this year and gained about 41% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/astrazeneca-unveils-expanded-facility-in-texas-aimed-at-doubling-production-of-hyperkalemia-drug/ch6nzBiR3No">AstraZeneca Unveils Expanded Facility In Texas Aimed At Doubling Production Of Hyperkalemia Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Sana Biotech Stock Jumps A Whopping 35% After Eric Jackson Calls It ‘Next 100-Bagger Platform’

Jackson added that he was long on the stock, while highlighting that the biotech company’s balance sheet is solid.

Enanta Pharmaceuticals (ENTA) on Monday announced that its mid-stage trial evaluating the efficacy and safety of Zelicapavir in outpatient adults with acute Respiratory Syncytial Virus (RSV) infection who are at high risk of complications failed to meet the primary endpoint.Shares of the company, however, rose 58% by Monday afternoon. Notably, the company also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-reports-positive-topline-results-its">stated</a> that a clinically meaningful improvement in time to complete resolution of all 13 RSV symptoms was observed for Zelicapavir compared to placebo, with a benefit of 2.2 days for the overall efficacy population and 6.7 days for patients with congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), or aged 75 and older.A lower hospitalization rate was observed for patients treated with Zelicapavir compared to placebo, and Zelicapavir demonstrated a robust antiviral effect, it added.The study, however, failed in its primary endpoint of lowering the time to resolution of lower respiratory tract disease symptoms to mild. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ENTA">ENTA stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_29_at_1_22_50_PM_png_995d6b1542.webp" alt="ENTA's Sentiment Meter and Message Volume as of 1:23 p.m. ET on Sept. 29, 2025 | Source: Stocktwits" width="576" height="65"><figcaption>ENTA's Sentiment Meter and Message Volume as of 1:23 p.m. ET on Sept. 29, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user cheered the rally.<stembedurl>https://stocktwits.com/JL_TradeZ/message/630342393</stembedurl>Another noted that though the trial missed the primary endpoint, the rest of the data “looks great.”<stembedurl>https://stocktwits.com/heyupikachu1821/message/630357384</stembedurl>Enanta said on Monday that Zelicapavir demonstrated a favorable safety profile in the trial and was well-tolerated. The goal of the study was to inform the design of a late-stage trial, including populations and endpoints, and no adverse events led to treatment discontinuation or study withdrawal in the Zelicapavir group.“We believe the totality of these data provides strong rationale for further clinical advancement of zelicapavir. Importantly, we identified multiple potential registrational endpoints for a Phase 3 trial,” said Chief Medical Officer Scott T. Rottinghaus.RSV is a common respiratory virus that infects the lungs and respiratory tract. Older adults are at significantly increased risk of severe illness due to the natural weakening of the immune system with age.ENTA stock has more than doubled this year and gained by about 20% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/kala-bio-stock-plunges-after-experimental-drug-fails-study/chDuP3wR3Ja">Kala Bio Stock Just Plunged 89% Today – Here’s What Happened</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, capsules are seen in a hand dressed in a medical glove with the Enanta Pharmaceuticals logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Enanta Pharmaceuticals Stock Rises 58% – Here’s An Important Update

The company reported that a lower hospitalization rate was observed in patients treated with Zelicapavir compared to those treated with placebo, and the drug demonstrated a robust antiviral effect.

Larimar Therapeutics, Inc. (LRMR) on Monday announced positive data from an ongoing long-term open-label study evaluating daily subcutaneous injections of Nomlabofusp in participants with Friedreich’s Ataxia.Friedreich's Ataxia (FA) is a rare, inherited disorder causing progressive damage to the nervous system, leading to symptoms like poor coordination, difficulty walking, and sensory loss, as well as heart disease and scoliosis. It is caused by a mutation in the FXN gene, resulting in a deficiency of the mitochondrial protein frataxin.In the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/29/3157570/0/en/Larimar-Therapeutics-Announces-Positive-Data-from-Ongoing-Long-term-Open-Label-Study-and-Updates-to-Nomlabofusp-Program-for-Friedreich-s-Ataxia.html">study,</a> an increase in skin frataxin (FXN) levels was observed with short- and long-term daily Nomlabofusp. All ten participants with data at six months achieved skin FXN levels over 50% of median levels in healthy volunteers, the company stated. It added that consistent directional improvement across multiple clinical outcomes was also observed after a year of Nomlabofusp treatment.“These new data, as well as the improvement in abnormal lipid profiles observed in prior completed studies, provide support that nomlabofusp increases FXN in patients with FA and that the strategy of FXN replacement has the potential to result in a clinical benefit,” said CEO Carole Ben-Maimon.Shares of the company tumbled 47% in the pre-market session after the company reported that anaphylaxis, or a severe allergic reaction, was observed in seven participants in the open-label study, and they were subsequently withdrawn from the study. Most instances of anaphylaxis occurred on the initial day of administration and most within the first six weeks of dosing, it noted.Other discontinuations in the study included three cases of generalized urticaria, one seizure, one vasovagal event, and two non-treatment-related discontinuations, it said.The company said that it consulted experts and decided to modify its starting dose regimen after the two most recent cases of anaphylaxis. The U.S. Food and Drug Administration has agreed with the approach, the company said. Larimar is looking to submit an application for approval of Nomlabofusp to the FDA in the second quarter of 2026.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LRMR">LRMR stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.LRMR stock is down by 2% this year and by 42% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pharma-lobby-announces-new-website-to-connect-patients-with-manufacturer-direct-patient-programs/chDuciYR3JJ">Pharma Lobby Announces New Website To Connect Patients With Manufacturer-Direct Purchase Programs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Larimar Therapeutics Stock Slumps Pre-market Over High Anaphylaxis Rate In Drug Study

The company said that anaphylaxis or a severe allergic reaction was reported in seven participants in the open-label study evaluating Nomlabofusp in participants with Friedreich’s ataxia. 

Harrow (HROW) announced on Friday that it has entered into an agreement to acquire privately held Melt Pharmaceuticals for an undisclosed price.While Harrow is a provider of ophthalmic disease management solutions, Melt Pharmaceuticals is focused on developing non-opioid therapies for sedation during medical procedures. Melt was spun out of Harrow in January 2019.The acquisition will <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.harrow.com/news-releases/news-release-details/harrow-acquire-melt-pharmaceuticals">include</a> Melt’s lead investigational therapy, MELT-300, a sublingually delivered formulation of a fixed dose of Midazolam (3mg) and Ketamine (50mg) designed to provide rapid, predictable sedation and analgesia without the need for intravenous administration.Shares of Harrow jumped 4% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/HROW">HROW stock</a> stayed within ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.MELT-300 was found to be statistically superior to both sublingual Midazolam alone and placebo in providing successful procedural sedation in a late-stage study. A recently completed cardiac safety study also indicated that MELT-300 did not alter normal heart rhythm, supporting the therapy’s safety profile. Harrow now plans to submit a new drug application to the U.S. Food and Drug Administration for the sedative in 2027, and is eyeing a commercial launch in the U.S. in 2028.If the FDA approves MELT-300, the company intends to discontinue the MKO Melt sedation product, marketed through its ImprimisRx subsidiary, for cataract surgeries. The company also sees potential for MELT-300 to be used in other procedures, including claustrophobia during MRIs, sedation for colonoscopies, dental procedures, gastroenterology procedures, and other interventions.The closing of the merger transaction, however, is subject to customary closing conditions, including approval by Melt shareholders, Harrow added.HROW stock is up 43% this year and by about 9% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/costco-draws-mixed-reactions-from-wall-street-despite-q4-beat-here-is-why/chDVjZGR3eX">Costco Draws Mixed Reactions From Wall Street Despite Q4 Beat: Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Harrow To Acquire Sedation Solutions Developer Melt Pharmaceuticals – More Details Inside

The acquisition will include Melt’s lead investigational therapy, MELT-300, designed to provide rapid, predictable sedation and analgesia without the need for intravenous administration. 

Shares of Rambus, Inc. (<a class="mention" data-mention="$RMBS" data-symbol-id="RMBS" href="https://stocktwits.com/symbol/RMBS" target="_blank">$RMBS</a>), a provider of Double Data Rate (DDR) memory interface chips, rose sharply early Tuesday, thanks to a positive analyst action.In a note published late-Tuesday, Baird analyst Tristan Gerra initiated coverage of Rambus with an&nbsp;‘Outperform’ rating and a $90 price target, which suggests scope for about 58% upside potential.The analyst noted that Rambus’ technology and IP is central to the artificial intelligence (AI)-driven performance increase in data centers. "Rambus is at the center of our 2025 semiconductor investment themes, which include AI memory, processors and optical systems," he said.&nbsp;Rambus has over 75% revenue exposure to data centers with AI becoming a major component of growth, Gerra said.&nbsp;He noted that the company is first to market with the October announcement of the "industry-first complete memory interface chipset for Gen 5 DDR5 RDIMM and next-generation MRDIMM." These bring much higher data transfer rates, lower latency and power consumption, he added.With the lineup, the company is poised to see a significant total addressable market expansion opportunity, Gerra said.The analyst sees major license deals with leading AI chip makers into the next year due to the HBM4 controller IP it announced in September that is expected to ramp in 2026.&nbsp;Rambus is poised to see significant growth, content increase, and share gains ahead, Baird said, adding that its data center chipset opportunity is estimated at $1.5 billion.<figure class="image"><a href="https://stocktwits.com/symbol/RMBS"><img style="aspect-ratio:631/138;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/rmbs_sentiment_5078361ebc.png" alt="rmbs-sentiment.png" width="631" height="138"></a><figcaption>RMBS sentiment and message volume November 26, 2024, as of 10:30 am ET | Source:&nbsp;Stocktwits</figcaption></figure>On Stocktwits platform, retailers turned ‘bullish’ (67/100) from a ‘neutral’ disposition a day ago, with message volume rising to ‘high’ level.At last check, Rambus was up 3.27% to $58.75.For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;Related Link:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/zoom-video-reports-beat-and-raise-q3-2025/cJIWZvyRgq">Zoom Video Stock Slumps Despite Beat-and-Raise Q3 But Retail Stays Connected</a>

Rambus shares have underperformed the broader market and the semiconductor industry this year.

Rambus Stock Powers Up After Memory Chipmaker Snags A Bullish Rating: Retail Upbeat

Rambus’ technology and IP is central to the artificial intelligence-driven performance increase in data centers, said Baird analyst Tristan Gerra.

Expectations are muted as Bath &amp; Body Works, Inc. (<a class="mention" data-mention="$BBWI" data-symbol-id="BBWI" href="https://stocktwits.com/symbol/BBWI" target="_blank">$BBWI</a>), a retailer of personal care and home fragrance products, prepares to report its third-quarter results before the market opens on Monday.Analysts, on average, expect the Columbus, Ohio-based company to report third-quarter adjusted earnings per share (EPS) of $0.47 on net sales of $1.58 billion. This compares to the year-ago numbers of $0.48 and $1.56 billion, respectively. The company guided to flat to a 2.5% increase in net sales, translating to $1.56-$1.6 billion.&nbsp;Ahead of the results, Citigroup said it expects above-consensus adjusted EPS due to a slightly stronger gross margin and lower spending, the Fly&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://thefly.com/news.php?symbol=BBWI">reported.</a> While conceding that the third quarter was another difficult quarter to drive sales, due to consumers remaining price-sensitive and the lack of big promotions to drive traffic, the firm said the second-half guidance is conservative enough.&nbsp;Citi believes that the fourth quarter is the best opportunity for the company to deliver upside to sales guidance this year. The firm has a Neutral rating and $35 price target for the stock. The risk/reward is skewed positive, going into the print, it said.Last week, JPMorgan analysts reduced its price target for the shares from $39 to $35.In early November, Bath &amp; Body Works announced a regular quarterly cash dividend of $0.20, payable on Dec. 6, to shareholders at the close of business on Nov. 22.The running quarter’s guidance is important, as it encompassed the holiday season. The forecast for this year’s industry-wide holiday sales is bright, with Bain &amp; Company<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bain.com/insights/2024-holiday-shopping-inside-latest-retail-sales-snap-chart/"> noting</a> a 5.4% year-on-year increase in October compared to September's 3.1% growth.&nbsp;"Santa’s sleigh has kicked into high gear for the start of the season," the firm said. Online sales grew 9.4%, in line with expectations, while in-store sales climbed a better-than-expected 4%, it added.Bath &amp; Body Works currently expects full-year net sales to fall by 2%-4%, with the 53rd week in 2023 representing a 100-basis-point headwind, and adjusted EPS of $3.02-$3.26.&nbsp;Bath &amp; Body Works shares have fallen about 27.33% for the year-to-date period.The average analysts’&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.tipranks.com/stocks/bbwi/forecast">price target&nbsp;</a>for Bath &amp; Body Works stock is $41.20, suggesting roughly 34% upside potential.<figure class="image"><a href="https://stocktwits.com/symbol/BBWI"><img style="aspect-ratio:637/130;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/bbwi_sentiment_064b8def79.png" alt="bbwi-sentiment.png" width="637" height="130"></a><figcaption>BBWI sentiment and message volume November 24, 2024, as of 9:40 pm ET | Source:&nbsp;Stocktwits</figcaption></figure>On Stocktwits, retail sentiment was ‘neutral’ (49/100), a deterioration from the ‘bullish’ mood that prevailed a day ago, while message volume was ‘normal.’The stock ended Friday’s session up 0.52% at $30.71.For updates and corrections email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/govx-siga-ebs-cmrx-stocks-gain-who-declares-who-public-health-emergency/cJId4JgRge">GeoVax, SIGA Jump After WHO Extends Mpox Public Emergency Status: Here’s What Retail Thinks</a>

The holiday quarter got off to a promising start, with a strong October, going by Bain & Co.’s estimates

Bath & Body Works Analyst Cautious Ahead Of Q3 Print: Retail Sentiment Deflates

Price-sensitive consumers and a lack of big promotional drive dampen outlook for Bath & Body Works’ third quarter, Citi said.

Current Price	$387.67
Prev Close	$392.00
Open	$391.50
Dividend Yield	N/A
50-Day Moving Average	$382.93
Beta	N/A
Avg. Volume	280,369.42
PE Ratio	N/A

52-Week High	$392.12
52-Week Low	$273.60
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

IWV
BlackRock Institutional Trust Company N.A. - iShares Russell 3000 ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IWV News

IWVBlackRock Institutional Trust Company N.A. - iShares Russell 3000 ETF